Imatinib Mesylate News and Research

RSS
Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of some forms of adult and pediatric chronic myelogenous leukemia (CML), and for the treatment of a rare form of cancer called gastrointestinal stromal tumor (GIST).

With CML, imatinib works by blocking an abnormal enzyme characteristic of the disease. In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells.

Imatinib is the first approved drug to directly turn off the signal of a protein known to cause a cancer. Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Imatinib is being investigated for its effectiveness against other kinds of cancer, as well, including acute lymphocytic leukemia and hypereosinophilic syndrome (HES).
Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Kinase inhibitors may offer new therapeutic approach for treatment of type 1 diabetes

Kinase inhibitors may offer new therapeutic approach for treatment of type 1 diabetes

Two common cancer drugs prevent, reverse type 1 diabetes

Two common cancer drugs prevent, reverse type 1 diabetes

Cancer requires support from immune system to develop, researchers report

Cancer requires support from immune system to develop, researchers report

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Researcher develops method for early detection of leukemia relapse

Researcher develops method for early detection of leukemia relapse

Could Gleevec help stroke victims?

Could Gleevec help stroke victims?

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Arsenic-based agent shown to help eradicate leukemia-initiating cells

Arsenic-based agent shown to help eradicate leukemia-initiating cells

Sunitinib may be associated with cardiac toxicity

Sunitinib may be associated with cardiac toxicity

Bosutinib safe, effective for chronic myelogenous leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

New role for miRNA in leukemia discovered

New role for miRNA in leukemia discovered

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Re-engineered Gleevec reduces heart risks

Re-engineered Gleevec reduces heart risks

Modified form of imatinib becomes more specific

Modified form of imatinib becomes more specific

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

Imatinib has ability to cure type of leukemia

Imatinib has ability to cure type of leukemia

Study suggests brain tumors need treatment with multiple 'targeted' drugs

Study suggests brain tumors need treatment with multiple 'targeted' drugs

Congestive heart failure is rare among leukemia patients who take imatinib

Congestive heart failure is rare among leukemia patients who take imatinib